News & Insights

At Prime Minister’s Questions on 19 October, Boris Johnson responded to Tory MP Crispin Blunt’s call to reschedule psilocybin. Johnson

Numinus has completed C$40.3 million in bought deal financing and recently reported quarterly revenues over C$500,000. In September the company

Small Pharma recently completed a Phase I trial to treat Major Depressive Disorder (MDD), with proprietary DMT formulation SPL026. The

On Monday, 4 October, PSYCH released the third edition of The Psychedelics as Medicine Report. The 200+ page report examines

In the research briefing: How ayahuasca ceremony leaders regard preparation and integration Psychedelics for treating neurodegenerative disorders such as Alzheimer’s

Professor David Nutt is the Chief Research Officer at Awakn Life Sciences. A former Director of the Neuropsychopharmacology Unit at Imperial

Robert Tessarolo has 25 years’ experience in the pharmaceutical industry, holding Chief Executive roles over two decades. Prior to his

Tryp Therapeutics stands apart from its peers by focusing on nociplastic pain, with the vast majority of companies exploring psychedelic

In 2019, RYAH Group pivoted towards becoming an Internet of Things (IoT) device platform, and as a result of the

Companies and investors are turning their attention to virtual and augmented reality technology, to enhance the impact and accessibility of

Beckley Psytech announced the completion of its oversubscribed Series B funding round, with US$80 million raised to develop psilocybin and

Last summer four Canadians received exemptions from the Controlled Drugs and Substances Act, to harness psilocybin in psychotherapy. Since the